COMMUNIQUÉS West-GlobeNewswire

ESPERITE N.V. (ESP) publishes its half-year report. Revenues and results were unexpectedly impacted by pending legal actions.
02/10/2017
CEO , Frédéric Amar will convert 1.5 million shares and will subscribe to 1 million new shares to support the business. Zutphen, The Netherlands - 2 October 2017 Esperite NV (Euronext: ESP, "Esperite" or "the Group") [...]
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
02/10/2017
Clareon ® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy of innovation including 100 [...]
TiGenix to host Analyst and Investor Event in New York City
02/10/2017
PRESS RELEASE TiGenix to host Analyst and Investor Event in New York City Leuven (BELGIUM) - October 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on [...]
TiGenix organisera une réunion d'analystes et d'investisseurs à New York
02/10/2017
COMMUNIQUÉ DE PRESSE TiGenix organisera une réunion d'analystes et d'investisseurs à New York Louvain (BELGIQUE) - 2 octobre 2017, 07h. CET - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société biopharmaceutique de [...]
ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
02/10/2017
REGULATED INFORMATION - INSIDE INFORMATION Caplacizumab meets primary endpoint and key secondary endpoints Statistically significant reduction in time to platelet count response, with at any given time patients treated [...]
ESPERITE N.V. (ESP) delays publication of 2017 Interim Financial Reporting
29/09/2017
Zutphen, The Netherlands - 29 September 2017 Esperite N.V. (Euronext: ESP, the " Company " or " Esperite ") announces that the Company expects to publish its Interim Financial Reporting on or before 2 October 2017. [...]
Summit Therapeutics plc : Exercise of Share Options
29/09/2017
Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 29 September 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]
MEDASYS : Chiffre d'affaires et résultats consolidés du 1er semestre 2017
29/09/2017
Clamart, le 29 septembre 2017 - Medasys, principal éditeur et intégrateur français de logiciels médicaux pour établissements de santé, publics et privés, dans les domaines du dossier patient, de la production de soins [...]
GUERBET : Mise à disposition du Rapport Financier semestriel 2017
29/09/2017
Villepinte, le 29 septembre 2017 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce ce jour avoir mis à la disposition du public et déposé auprès [...]
Khiron Appoints Former DEA Chief of Pharmaceutical Investigations to Advisory Board
29/09/2017
TORONTO, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Khiron Life Sciences Corp. (" Khiron " or the " Company ") reports the appointment of Mr. Matthew Murphy, the former U.S. Drug Enforcement Administration ("DEA") Chief of [...]
Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US
29/09/2017
Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp ® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment [...]
CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia
29/09/2017
Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has endorsed an update of the EU label with [...]
Ambu A/S: Financial Diary
29/09/2017
Financial Diary 2017/18 31 October 2017: Deadline for the inclusion of specific items on the agenda of the annual general meeting 2016/17 9 November 2017: Annual Report 2016/17 (Earnings release) 13 December 2017: [...]
Total number of shares and voting rights in Zealand at September 30, 2017
29/09/2017
Company announcement - No. 47 / 2017 Total number of shares and voting rights in Zealand at September 30, 2017 Copenhagen, September 29, 2017 - In accordance with Section 10 of the Danish Statutory Order on Issuers' [...]
To Enable Better Targeting Of Resources, Skåne University Hospital Starts To Use New Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease (CAD)
29/09/2017
Press release Malmö, September 29, 2017 On World Heart Day Latest Data Shows Heart Disease Remains Most Common Cause of Death in Sweden To Enable Better Targeting Of Resources, Skåne University Hospital Starts To Use [...]
Solon Eiendom ASA : Primary insider notification
29/09/2017
(Oslo, Norway, 28 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 10,000 shares in Solon Eiendom ASA at a price of NOK 18.3839 per [...]
DXS International plc : Final Results
29/09/2017
DXS INTERNATIONAL PLC Final Results for the year ended 30 April 2017 The Board of DXS International plc ("the Company") is pleased to announce its audited Final Results for the year ended 30 April 2017. Although the [...]
Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis
28/09/2017
Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a single ascending dose (SAD) study Observed clinical efficacy and reductions in markers of inflammation [...]
AB Science annonce que des données cliniques et précliniques du masitinib dans la SLA ont été retenues pour être présentées oralement lors de 6 conférences internationales en 2017
28/09/2017
Paris, 28 septembre 2017, 19h30 Présentation de données cliniques et précliniques du masitinib dans la Sclérose Latérale Amyotrophique (SLA) dans six grandes conférences internationales De nouvelles données précliniques [...]

Pages